Specialty drugs in the United States

Evolent Health Announces Agreement to Acquire Vital Decisions, Expanding its Depth and Breadth in Specialty Care Management

Retrieved on: 
Wednesday, August 4, 2021
Medical specialty, Health care, Articles, Health informatics, Specialty drugs in the United States

Vital Decisions will report into Evolent's specialty management offering, New Century Health, and will be consolidated into Evolent's Clinical Solutions segment.

Key Points: 
  • Vital Decisions will report into Evolent's specialty management offering, New Century Health, and will be consolidated into Evolent's Clinical Solutions segment.
  • Founded in 2002, New Century Health is a specialty care management company focused on driving improved outcomes in oncology and cardiology through peer-led provider collaboration.
  • We look forward to welcoming Vital Decisions employees and clients to the Evolent and New Century Health families."
  • Evolent Health (NYSE: EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable.

AscellaHealth and Appro-Rx Partner to Provide Specialty Pharmacy Services for Improved Patient Outcomes and Lower Payer Costs

Retrieved on: 
Tuesday, August 3, 2021
Technology, Hospitals, Other Technology, Software, Practice Management, Managed care, Health, Pharmaceutical, Data management, Health sciences, Life sciences, Health care, Pharmacy, Specialty drugs, Clinical pharmacology, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Specialty pharmacy, Adherence, Prescription drug

Dea Belazi, president and CEO, AscellaHealth, says, “This exciting partnership will support advances in specialty medication compliance and foster a high level of plan member satisfaction -- while helping payers rein in the staggering costs of specialty drugs.”

Key Points: 
  • AscellaHealth , a global specialty pharmacy and healthcare solutions company, today announces a partnership with Appro-Rx , a national prescription benefit management company, to become its specialty pharmacy services and solutions provider.
  • Specialty drugs are vastly more expensive than their traditional drug counterparts, and this partnership not only enables our clients to realize significant cost savings but also to improve health outcomes for their employees.
  • AscellaHealths innovative specialty pharmacy and infusion services provide cost-saving discounts on prescription medications with timely access to therapies, data-driven reporting and patient support programsall of which help to improve patient adherence and health outcomes, thereby optimizing the patient journey.
  • AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services.

McKesson Raises Quarterly Dividend by 12% to $0.47 Per Share

Retrieved on: 
Monday, July 26, 2021
Public policy, Government, Pharmaceutical, General Health, Health, Medical devices, Healthcare reform, Supply chain management, Retail, McKesson Corporation, Pharmacy, MCK, Healthcare industry, Companies, Economy of the United States, Health care, McKesson Europe, Specialty drugs in the United States

The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 23, 2021 a regular dividend of $0.47 per share of common stock, a 12% increase from $0.42 per share in the prior quarter.

Key Points: 
  • The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 23, 2021 a regular dividend of $0.47 per share of common stock, a 12% increase from $0.42 per share in the prior quarter.
  • The dividend will be payable on October 1, 2021, to stockholders of record on September 1, 2021.
  • McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions.
  • McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.

Ryan Specialty Announces Pricing of its Initial Public Offering

Retrieved on: 
Thursday, July 22, 2021
Professional services, Insurance, Finance, Initial public offering, Underwriting, Financial markets, Intact Insurance Specialty Solutions, Finance, Stock market, Specialty drugs in the United States

Ryan Specialty Group Holdings, Inc. (Ryan Specialty) today announced the pricing of its initial public offering of 56,918,278 shares of its Class A common stock at a price to the public of $23.50 per share, before underwriting discounts and commissions, for gross proceeds of $1,337.6 million.

Key Points: 
  • Ryan Specialty Group Holdings, Inc. (Ryan Specialty) today announced the pricing of its initial public offering of 56,918,278 shares of its Class A common stock at a price to the public of $23.50 per share, before underwriting discounts and commissions, for gross proceeds of $1,337.6 million.
  • Additionally, Ryan Specialty has granted the underwriters a 30-day option to purchase up to an additional 8,537,742 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions.
  • Upon completion of the initial public offering, Ryan Specialty will be the sole managing member of Ryan Specialty Group, LLC (Ryan Specialty Group) and will exclusively operate and control all of its business and affairs.
  • Founded by Patrick G. Ryan in 2010, Ryan Specialty Group is a rapidly growing service provider of specialty products and solutions for insurance brokers, agents and carriers.

Navitus Health Solutions Continues Growth with Acquisitions of EpiphanyRx and Quality Drug Clinical Care

Retrieved on: 
Monday, July 19, 2021
Managed care, Pharmaceutical, Health, Health sciences, Life sciences, Pharmaceutical sciences, Pharmacy, Specialty drugs, Medicinal chemistry, Symbols, Specialty pharmacy, Pharmaceuticals policy, Specialty drugs in the United States, Avella Specialty Pharmacy, Navitus, Lumicera Health Services, EpiphanyRx, Quality Drug Clinical Care, NAVITUS, LUMICERA HEALTH SERVICES, EPIPHANYRX, QUALITY DRUG CLINICAL CARE

Lumicera Health Services, Navitus wholly-owned specialty pharmacy, has also purchased Quality Drug Clinical Care, a specialty pharmacy serving patients with HIV in Irvine, CA, to better serve patients located in the western United States.

Key Points: 
  • Lumicera Health Services, Navitus wholly-owned specialty pharmacy, has also purchased Quality Drug Clinical Care, a specialty pharmacy serving patients with HIV in Irvine, CA, to better serve patients located in the western United States.
  • Navitus continues to evolve and grow to deliver the highest quality clinical value and lowest net costs to our customers through our full pass-through, transparent business model, said David Fields, President & CEO, Navitus.
  • We are thrilled that Quality Drug Clinical Care has joined our growing network of Lumicera specialty pharmacies, said Sharon Faust, Vice President, Specialty Pharmacy, Lumicera Health Services.
  • Quality Drug Clinical Care helps its customer with their specialty medication and provide ongoing, personalized support.

Shorla Pharma Expands into the U.S. with the Opening of a Cambridge, MA Office

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Life sciences, Industry economics), Pharmaceutical companies, Biopharmaceuticals, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Sun Pharma

Shorla Pharma Limited (Shorla), a specialty pharmaceutical company, has announced its arrival in the United States locating a base in Boston's innovative Cambridge biotech cluster.

Key Points: 
  • Shorla Pharma Limited (Shorla), a specialty pharmaceutical company, has announced its arrival in the United States locating a base in Boston's innovative Cambridge biotech cluster.
  • Founded in Ireland, Shorla specializes in developing innovative oncology drugs, with a focus on orphan and pediatric cancers, and is rapidly building its U.S. team, headquartered in Cambridge, MA.
  • The company has an advanced pipeline of oncology products to treat a number of unmet patient needs.
  • "It's an honor to bring Shorla's life-changing treatments to patients in the U.S.," said Sharon Cunningham, CEO and Co-founder of Shorla Pharma.

TailorMed Collaborates with AllianceRx Walgreens Prime to Reduce Patient Out-of-Pocket Costs

Retrieved on: 
Wednesday, July 14, 2021
General Health, Health, Pharmaceutical, Technology, Software, Walgreens, Life sciences, Biotechnology, Specialty drugs in the United States, Articles, TailorMed, AllianceRx Walgreens Prime, TAILORMED, ALLIANCERX WALGREENS PRIME

AllianceRx Walgreens Prime will leverage TailorMeds platform to quickly identify financial assistance programs for patients at risk of not affording the specialty medications needed to treat their chronic condition or rare disease.

Key Points: 
  • AllianceRx Walgreens Prime will leverage TailorMeds platform to quickly identify financial assistance programs for patients at risk of not affording the specialty medications needed to treat their chronic condition or rare disease.
  • We are excited to leverage TailorMeds technology to help lower specialty prescription costs for our patients, said Lisa Mymo, vice president, Pharma and Financial Services at AllianceRx Walgreens Prime.
  • We are thrilled to be working with AllianceRx Walgreens Prime, a forward-thinking organization that puts its patients at the center of everything they do, said Srulik Dvorsky, co-founder and CEO of TailorMed.
  • The work between AllianceRx Walgreens Prime and TailorMed will address this at scale, helping make specialty prescriptions affordable for patients across the country.

Jacobson Pharma Announces FY2021 Annual Results

Retrieved on: 
Tuesday, June 29, 2021
Life sciences, Biotechnology, Articles, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Pharma

HONG KONG, June 29, 2021 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2021 (the "FY2021" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2021 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2021 (the "FY2021" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated with the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2021 ACN Newswire .

New Paper Explores How Biosimilars Expand Cancer Treatment Options

Retrieved on: 
Tuesday, June 29, 2021
Life sciences, Articles, Health sciences, Biotechnology, Pharmaceutical industry, Specialty drugs, Biopharmaceutical, Pharmacy, Biosimilar, Shared decision-making in medicine, Patient advocacy, Specialty drugs in the United States

WASHINGTON, June 29, 2021 /PRNewswire/ -- A new paper from the Alliance for Patient Access (AfPA), a national nonprofit patient advocacy organization, explores how biosimilars offer more treatment options for people living with cancer.

Key Points: 
  • WASHINGTON, June 29, 2021 /PRNewswire/ -- A new paper from the Alliance for Patient Access (AfPA), a national nonprofit patient advocacy organization, explores how biosimilars offer more treatment options for people living with cancer.
  • Biologics, including biosimilars, are typically injected or infused to treat conditions such as arthritis, high cholesterol, migraine or cancer.
  • Biosimilars stand to benefit both physicians and cancer patients in several ways, the paper explains.
  • The paper reinforces the need for shared decision-making between patients and their providers and policies that support access to all cancer care options.

AMS 2020 Specialty Drug Trends Report Highlights Egregious Overspend

Retrieved on: 
Tuesday, June 22, 2021
Life sciences, Articles, Biotechnology, Business intelligence, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Predictive analytics

LYNNFIELD, Mass., June 22, 2021 /PRNewswire/ --AMS, a healthcare IT company that provides clinical insights and financial analysis of the costliest and most complex medical claims, released their 2020 Specialty Drug Trends Report today, highlighting the need for predictive analytics to combat pervasive drug overspend.

Key Points: 
  • LYNNFIELD, Mass., June 22, 2021 /PRNewswire/ --AMS, a healthcare IT company that provides clinical insights and financial analysis of the costliest and most complex medical claims, released their 2020 Specialty Drug Trends Report today, highlighting the need for predictive analytics to combat pervasive drug overspend.
  • AMS research reveals that payers are not being judicious with their specialty drug expenditures because they have little insight into the actual drivers of high-cost claims and members.
  • Fewer than 2% of the U.S. population utilized specialty drugs
    Notable for this year's report, specialty drug costs and trends sections were greatly expanded, allowing for greater depth & breadth of data.
  • "As one can see from the report, specialty drug prices are high enough already.